ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2003
Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 60 citations in OpenAlex.
- NIR-II scattering gold superclusters for intravascular optical coherence tomography molecular imaging.Nature nanotechnology · 2025Article
- Recent Advances in Nanomaterials for Asthma Treatment.International journal of molecular sciences · 2022Review
- Magnetic Functionalized Nanoparticles for Biomedical, Drug Delivery and Imaging Applications.Nanoscale research letters · 2019Review
- DNA damage following pulmonary exposure by instillation to low doses of carbon black (Printex 90) nanoparticles in mice.Environmental and molecular mutagenesis · 2015Article
- Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.British journal of pharmacology · 2014Review
- Microvascular targets for anti-fibrotic therapeutics.The Yale journal of biology and medicine · 2013Review
- Article
- Nanomedicine for respiratory diseases.Tanaffos · 2012Review
- Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent.Investigational new drugs · 2010Article
- Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins.Langmuir : the ACS journal of surfaces and colloids · 2008Article
- Pulmonary applications and toxicity of engineered nanoparticles.American journal of physiology. Lung cellular and molecular physiology · 2008Review
- Immunological properties of engineered nanomaterials.Nature nanotechnology · 2007Review
- Nanoparticles in modern medicine: state of the art and future challenges.International journal of nanomedicine · 2007Review
- Nanomaterials, inflammation, and tissue engineering.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The severity of allergic asthma is dependent, in part, on the intensity of peribronchial inflammation. P-selectin is known to play a role in the development of allergen-induced peribronchial inflammation and airway hyperreactivity. Selective inhibitors of P-selectin-mediated leukocyte endothelial-cell interactions may therefore attenuate the inflammatory processes associated with allergic airway disease. Novel P-selectin inhibitors were created using a polyvalent polymer nanoparticle capable of displaying multiple synthetic, low molecular weight ligands. By assembling a particle that presents an array of groups, which as monomers interact with only low affinity, we created a construct that binds extremely efficiently to P-selectin. The ligands acted as mimetics of the key binding elements responsible for the high-avidity adhesion of P-selectin to the physiologic ligand, PSGL-1. The inhibitors were initially evaluated using an in vitro shear assay system in which interactions between circulating cells and P-selectin-coated capillary tubes were measured. The nanoparticles were shown to preferentially bind to selectins expressed on activated endothelial cells. We subsequently demonstrated that nanoparticles displaying P-selectin blocking arrays were functionally active in vivo, significantly reducing allergen-induced airway hyperreactivity and peribronchial eosinophilic inflammation in a murine model of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.